Few pharmaceutical companies can match our combination of capabilities in small molecules, biologics, immunotherapies and protein engineering.
Our biologics pipeline has matured in recent years resulting in a 50-50 balance of small molecule programmes and biologics in the clinical portfolio.
By playing an active role in the use and development of biologics, we can attack diseases that were not amenable to traditional small-molecule approaches.
Our MedImmune site in Cambridge is its European research & development site, focusing on discovering and developing antibodies and other therapeutic proteins across a range of therapy areas. Please visit the MedImmune website for more information.